Ahmed Glaucoma Valve Implant Outcomes Improve With Antifibrotic Use

This article originally appeared here.
Adjuvant treatment following AGV implantation improves treatment success, cuts hypertensive phase
Adjuvant treatment following AGV implantation improves treatment success, cuts hypertensive phase

HealthDay News — Mitomycin C (MMC) and 5-flurouracil (5-FU) improve outcomes following Ahmed glaucoma valve (AGV) implantation, according to a study published online August 4 in Clinical & Experimental Ophthalmology.

Qi N. Cui, MD, PhD, from the University of California in San Francisco, and colleagues examined the effect of MMC and 5-FU on treatment outcomes for 50 patients who received AGV implantation. Patients received intraoperative MMC followed by postoperative injections of MMC and/or 5-FU (+INJECTION) group (26 patients/eyes) or not (−INJECTION; 24 patients/eyes).

The researchers observed higher treatment success in the +INJECTION group versus the −INJECTION group (86 versus 58%; P=0.04). At one, three, six, and 12 months, intraocular pressure was lower in the +INJECTION group versus the −INJECTION group. In the +INJECTION group, hypertensive phase (HP) occurred less often (3.8 percent, compared to 54% in the −INJECTION group; P=0.021). At one, three, six, and 12 months, fewer medications were required by the +INJECTION group. Comparable complication rates were seen between the +INJECTION and −INJECTION groups (46.2 and 54.2%, respectively; P=0.63).

"Adjuvant treatment with antifibrotics following AGV implantation decreased the HP and improved surgical outcomes without impacting complication rates at one year," the authors write. "This study postulates a role for antifibrotics in the postoperative management of AGV implantation."

Abstract
Full Text (subscription or payment may be required)

Loading links....